Phase 2
N=30
N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)
GM2 Gangliosidosis · Tay-Sachs Disease · Sandhoff Disease
Bottom Line
View on ClinicalTrials.gov: NCT03759665 ↗Enrolled (actual)
30
Serious AEs
3.3%
Results posted
Mar 2024
Primary outcome: Primary: Clinical Impression of Change in Severity (CI-CS) [Fields et al 2021] — 0.71 score on a scale — p=0.044
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- IB1001 (Drug)
- Age
- Pediatric, Adult, Older Adult · 6+ yrs
- Sex
- All
- Sponsor
- IntraBio Inc
- Primary completion
- Jan 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clinical Impression of Change in Severity (CI-CS) [Fields et al 2021] |
0.71 | 0.044 sig |
| SECONDARY Key Secondary Endpoint: Individual Components of the CI-CS |
0.34; -0.36 | — |
| SECONDARY Key Secondary Endpoint: Change in Severity Based on Average CI-S |
0.09 | 0.206 |
| SECONDARY Key Secondary Endpoint: CI-CS Score Reclassified on a 3-Point Scale |
12; 1; 16; 16; 3; 8 | — |
| SECONDARY Key Secondary Endpoint: CI-CS Score for the Non-Primary Anchor Test |
-0.30; 0.23 | — |
| SECONDARY Spinocerebellar Ataxia Functional Index (SCAFI) [Schmitz-Hübsch et al, 2008] |
0.0163; -0.0080 | 0.210 |
| SECONDARY Scale for Assessment and Rating of Ataxia (SARA) Score [Schmitz-Hübsch Etal, 2006; Subramony, 2007] |
-1.41; 1.43 | <0.001 sig |
| SECONDARY EuroQuol- 5 Dimension (EQ-5D) Quality of Life Scale: Visual Analogue Scale (VAS) |
71.3; 71.1 | — |
| SECONDARY Modified Disability Rating Scale (mDRS) [Iturriaga et al. 2006] |
-0.030; 0.042 | 0.020 sig |
| SECONDARY Investigator's Clinical Global Impressions of Change (CGI-c) |
3.2; 4.9 | <0.001 sig |
| SECONDARY Parent/Caregiver's Clinical Global Impression of Change (CGI-C) |
3.2; 4.8 | — |
| SECONDARY Patient's Clinical Global Impressions (CGI) if Able |
3.0; 4.6 | — |
Summary
This is a multinational, multicenter, open-label, rater-blinded prospective Phase II study which will assess the safety and efficacy of N-Acetyl-L-Leucine (IB1001) for the treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease).
There are two phases to this study: the Parent Study, and the Extension Phase.
The Parent Study evaluates the safety and efficacy of N-Acetyl-L-Leucine (IB1001) in the symptomatic treatment of GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease).
The Extension Phase evaluates the long-term safety and efficacy of IB1001 for the neuroprotective, disease-modifying treatment of GM2 Gangliosidosis. The Extension Phase was considered exploratory.
Eligibility Criteria
Parent Study Inclusion Criteria
Individuals who meet all of the following criteria are eligible to participate in the study:
- Written informed consent signed by the patient and/or their legal representative/ parent
- Male or female aged ≥6 years in Europe OR ≥18 years in the United States with a confirmed diagnosis of GM2 Gangliosidosis ( i.e., clinical features and positive genetic test GM2-gangliosidosis caused by β-hexosaminidase deficiency resulting from mutations in the HEXA or HEXB genes) at the time of signing informed consent.
- Females of childbearing potential, defined as a premenopausal female capable of becoming pregnant, will be included if they are either sexually inactive (sexually abstinent for 14 days prior to the first dose continuing through 28 days after the last dose) or using one of the following highly effective contraceptives (i.e. results in 5x upper limit of normal (ULN);
- Total bilirubin >1.5x ULN, unless Gilbert's syndrome is present in which case total bilirubin >2x ULN.
- Known or persistent use, misuse, or dependency of medication, drugs, or alcohol.
- Current or planned pregnancy or women who are breastfeeding.
- Patients with severe vision or hearing impairment (that is not corrected by glasses or hearing aids) that, at the investigator's discretion, interferes with their ability to perform study assessments.
- Patients who have been diagnosed with arthritis or other musculoskeletal disorders affecting joints, muscles, ligaments, and/or nerves that by themselves affects patient's mobility and, at the investigator's discretion, interferes with their ability to perform study assessments.
- Patients unwilling and/or not able to undergo a 6-week washout period from any of the following prohibited medication prior to Visit 1 (Baseline 1) and remain without prohibited medication through Visit 6.
- Aminopyridines (including sustained-release form);
- N-Acetyl-DL-Leucine (e.g. Tanganil®);
- N-Acetyl-L-Leucine (prohibited if not provided as IMP);
- Riluzole;
- Gabapentin;
- Varenicline;
- Chlorzoxazone;
- Sulfasalazine;
- Rosuvastatin.
Extension Phase Inclusion Criteria
- Completed Visit 6 of the IB1001-202 Parent Study
- The Principal Investigator determines further treatment with IB1001 to be in the patient's best interest
- Written informed consent signed by the patient and/or their legal representative/parent/ impartial witness for participation in the Extension Phase
- Patients are willing to continue to remain without the following prohibited medication from Visit 6 throughout the duration of the Extension Phase:
Aminopyridines (including sustained-release form); b) N-Acetyl-DL-Leucine (e.g. Tanganil®); c) N-Acetyl-L-Leucine (prohibited if not provided as IMP); d) Riluzole; e) Gabapentin; f) Varenicline; g) Chlorzoxazone; h) Sulfasalazine; i) Rosuvastatin.
Data sourced from ClinicalTrials.gov (NCT03759665). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.